Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9611358 | 1.00 | BACE1 (0.41) | BACE1BACE2KLK7TACR1DDB1 | |
| SCHEMBL9613455 | 0.86 | BACE1 (0.36) | BACE1BACE2 | |
| SCHEMBL9611499 | 0.83 | KLK7 (0.42) | KLK7 | |
| SCHEMBL8350117 | 0.77 | CHRM2 (0.40) | — | |
| SCHEMBL9611359 | 0.77 | KLK7 (0.46) | KLK7 | |
| SCHEMBL8515007 | 0.77 | KLK7 (0.46) | KLK7 | |
| SCHEMBL8510451 | 0.76 | GPR119 (0.40) | TACR1GPR119 | |
| SCHEMBL9611316 | 0.76 | GPR119 (0.40) | TACR1GPR119 | |
| SCHEMBL9611290 | 0.76 | USP30 (0.42) | KLK7TACR1GPR119 | |
| SCHEMBL2724151 | 0.76 | USP30 (0.42) | KLK7TACR1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415486-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120135990-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2434890-A1 | IAP INHIBITORS | Tetralogic Pharmaceuticals Corp. (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010138666-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135990-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | BACE1 33/4885BACE2 41/4885KLK7 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.